Therapeutic and chemical developments of cholecystokinin receptor ligands

Bibliography

• MUTT V, JORPES E: Hormonal polypeptides in theupper intestine. Biochem. J. (1974) 125:57P–58P.
   Google Scholar
• LARSSON LI, REHFELD JF: Localization and molecularheterogeneity of cholecystokinin in the central and peripheral nervous system. Brain Res. (1979) 165:201–218.
   PubMed Web of Science ®Google Scholar
• REEVE JR, EYSSELEIN V, WALSH JH, BEN-AVRAM CM,SHIVELY JE: New molecular forms of cholecystokinin. Microsequence analysis of forms previously charac-terized by chromatographic methods. J. Biol. Chem. (1986) 261:16392–16397.
   Google Scholar
• MATON PN, SELDEN AC, CHADWICK VS: Large and smallforms of cholecystokinin in human plasma: measure-ment using high pressure liquid chromatography and radioimmunoassay. Regul. PepL (1982) 4:251–260.
   PubMed Web of Science ®Google Scholar
• CRAWLEY J, ST-PIERRE S, GAUDREAU P: Analysis of thebehavioral activity of C- and N-terminal fragments of cholecystokinin octapeptide. J. Pharmacol Exp. Ther. (1984) 230:438–444.
   PubMed Web of Science ®Google Scholar
• •Determination of the minimal CCK sequence required for total activity.
   Google Scholar
• LIDDLE RA: Cholecystokinin cells. Ann. Rev. Physiol (1997) 59:221–242.
   PubMed Web of Science ®Google Scholar
• ••Review concerning the physiological processes leading toCCK release.
   Google Scholar
• NILSON G: In: Gastrointestinal Hormones. GBJ Glass (Ed.),Raven Press, New York, USA 127.
   Google Scholar
• LEE YM, BEINBORN M, MCBRIDE EW, LU M,KOLAKOWSKI LF JR, KOPIN AS: The human brain cholecystokinin-BIgastrin receptor. Cloning and characterization. J. Biol. Chem. (1993) 268:8164–8169.
   PubMed Web of Science ®Google Scholar
• SOLL AH, AMIRIAN DA, PARK J, ELASHOFF JD, YAMADA T:Cholecystokinin potently releases somatostatin from canine fundic mucosal cells in short-term culture. Am. Physiol (1985) 248:G569–573.
   Google Scholar
• LIDDLE RA: Cholecystokinin. In: Gut Peptides. Walsh JH,Dockray GJ (Eds.), Raven Press, New York, USA (1994):175–216.
   Google Scholar
• SCHJOLDAGER B, MOLERO X, MILLER LJ: Functional andbiochemical characterization of the human gallbladder muscularis mucosa. Gastroenterology (1989) 96:1119–1125.
   PubMed Web of Science ®Google Scholar
• MORINI G, BAROCELLI E, IMPICCIATORE M, GRIDER JR,MAKHLOUF GM : Receptor type for cholecystokinin on isolated intestinal muscle cells of the guinea pig. Regul PepL (1990) 28:313–321.
   PubMedGoogle Scholar
• MORAN TH, ROBINSON P, GOLDRICH MS, MCHUGH T:Two brain cholecystokinin receptors: implications for behavioral actions. Brain Res. (1986) 362:175–179.
   PubMed Web of Science ®Google Scholar
• MORAN TH: Cholecystokinin in the central nervous system. Regul. PepL Lett. (1994) 6:6-15. Interesting review of the CCK's role in the CNS.
   Google Scholar
• LOTSTRA F, VANDERHAEGHEN J: Distribution of immunoreactive cholecystokinin in the human hippocampus. Peptides (1987) 8:911–920.
   PubMed Web of Science ®Google Scholar
• PERSSON H, ERICSSON A, SCHALLING M, RHEFELD JF,HOKFELT T: Detection of cholecystokinin in spermato-genic cells. Acta Physiol. Scand. (1988) 134:565–566.
   PubMedGoogle Scholar
• MAKOVEC F, PERIS W, REVEL W, GIOVANETTI R, MENNUMI L, ROVATI LC: Structure-antigastrin activity relationships of new (R)-4-benzamido-5--oxopentanoic acid derivatives. J. Med. Chem. (1992) 35:28–38.
   PubMed Web of Science ®Google Scholar
• CRAWLEY JN, CORWIN RL: Biological actions of cholecystokinin. Peptides (1994) 15:731–755.
   PubMed Web of Science ®Google Scholar
• ••Very important and complete overview of the biologicalactions of CCK.
   Google Scholar
• LIDDLE RA, GERTZ BJ, KANAYAMA S et al.: Effects of anovel cholecystokinin (CCK) receptor antagonist, MK-329, on gallbladder contraction and gastric emptying in humans. Implications for the physiology of CCK../. Clin. Invest. (1989) 84:1220–1225.
   PubMed Web of Science ®Google Scholar
• FRIED M, ERLACHER U, SCHWIZER W et al.: Role ofcholecystokinin in the regulation of gastric emptying and pancreatic enzyme secretion in humans: studies with the cholecystokinin-receptor antagonist loxiglu-mide. Gastroenterology (1991) 101:503–511.
   PubMed Web of Science ®Google Scholar
• •Highlight on CCK in the GI motility function.
   Google Scholar
• JENSEN RT, WANK SA, ROWLEY WH, SATO S, GARDNERJD: Interaction of CCK with pancreatic acinar cells. Trends Pharmacol Sci. (1989) 10:418–423.
   PubMed Web of Science ®Google Scholar
• KARLSSON S, AHREN B: CCK-8 stimulated insulinsecretion in vivo is mediated by CCK-A receptors. Eur. Pharmacol (1992) 213:145–146.
   PubMed Web of Science ®Google Scholar
• MEYER BM, WERTH BA, BEGLINGER C et al: Role of cholecystokinin in regulation of gastrointestinal motor functions. Lancet (1989) 2:12–15.
   PubMed Web of Science ®Google Scholar
• •Role of CCK in the GI regulation.
   Google Scholar
• LIBERGE M, ARRUEBO MP, BUENO L: Role of hypotha-lamic cholecystokinin octapeptide in the colonic motor response to a meal in rats. Gastroenterology (1991) 100:441–49.
   PubMed Web of Science ®Google Scholar
• BEGLINGER C, HILDEBRAND P, MEIER R et al. : A physio-logical role for cholecystokinin as a regulator of gastrin secretion. Gastroenterology (1992) 103:490–495.
   PubMed Web of Science ®Google Scholar
• LLOYD DC, RAYBOULD HE, WALSH JH: Cholecystokinininhibits gastric acid secretion through type 'A' cholecystokinin receptors and somatostatin in rats. Am. J. Physiol. (1992) 263:G287–G292.
   Google Scholar
• HERSEY SJ, MAY D, SCHYBERG D: Stimulation ofpepsinogen release from isolated gastric glands by cholecystokininlike peptides. Am. J. Physiol (1983) 244:G192–197.
   PubMed Web of Science ®Google Scholar
• MOODY TW, CUTTITTA F: Growth factor and peptidereceptors in small cell lung cancer. Life Sci. (1993) 52:1161–1173.
   PubMed Web of Science ®Google Scholar
• REHFELD JF, VAN SOLINGE WW: The tumor biology ofgastrin and cholecystokinin. Adv. Cancer Res. (1994) 63:295–347.
   PubMed Web of Science ®Google Scholar
• GIBBS J, YOUNG RC, SMITH GP: Cholecystokinindecreases food intake in rats. J. Comp. Physiol. Psycho]. (1973) 84:488–495.
   PubMed Web of Science ®Google Scholar
• •First description of the role of cCK in the food intake.
   Google Scholar
• HOLZER HH, TURKELSON CM, SOLOMON TE, RAYBOULD HE: Intestinal lipids inhibits gastric emptying via CCK and a vagal capsaicin afferent pathway in rats. Am. J. Physiol. (1994) 267:G625–G629.
   Google Scholar
• RAVARD S, DOURISH CT: Cholecystokinin and anxiety. Trends Pharmacol. Sci. (1990) 11:271–273.
   PubMed Web of Science ®Google Scholar
• ••Review about the pjhysiological interest of CCK in anxietypathology.
   Google Scholar
• DAUGE V, LENA I: CCK in anxiety and cognitive processes. Neurosci. Biobehav. Rev. (1998) 22:815–825.
   PubMed Web of Science ®Google Scholar
• •Relations between CCK and the different CNS processes.
   Google Scholar
• AKAIKE A, TAMURA Y, SATO Y et al: Cholecystokinin- induced protection of cultured cortical neurons against glutamate neurotoxicity. Brain Res. (1991) 557:303–307.
   PubMed Web of Science ®Google Scholar
• HUGHES J, HUNTER JC, WOODRUFF GN: Neurochemical actions of CCK underlying the therapeutic potential of CCK-B antagonists. Neuropeptides (1991) 19:85–89.
   PubMed Web of Science ®Google Scholar
• VOIGT M, WANG RY, WESTFALL TC: Cholecystokinin octapeptides alter the release of endogenous dopamine from rat nucleus accumbens in vitro. J. Pharmacol. Exp. Ther. (1986) 237:147–153.
   PubMed Web of Science ®Google Scholar
• JENSEN RT: CCKB/gastrin receptor antagonists: recent advances and potential uses in gastric secretory disorders. Yale J. Biol. Med. (1996) 69:245–259.
   PubMed Web of Science ®Google Scholar
• ••Overview of the therapeutic interest of CCK-BR antagonists.
   Google Scholar
• WANK SA: G Protein-coupled receptors in gastrointes- tinal physiology I. CCK receptors: an exemplary family. Am. J. Physiol (1998) 274:G607–G613.
   Google Scholar
• ••Description of the biological actions of CCK-R in the GIphysiology.
   Google Scholar
• SHULKES A, BLADWIN GS: Biology of gut cholecys- tokinin and gastrin receptors. Clin. Exp. Pharmacol Physiol. (1997) 24:209–216.
   PubMed Web of Science ®Google Scholar
• ••Review concerning the biological relations between CCKand gastrin receptors.
   Google Scholar
• INNIS RB, SNYDER SH: Distinct cholecystokinin receptors in brain and pancreas. Proc. Natl Acad. Sci. USA (1980) 77:6917–6921.
   PubMed Web of Science ®Google Scholar
• DOURISH CT, HILL DR: Classification and function of CCK receptors. Trends Pharmacol Sci. (1987) 8:207–208.
   Web of Science ®Google Scholar
• LEE YM, BEINBORN M, MCBRIDE EW, LU M, KOLAKOWSKI LF JR, KOPIN AS: The human brain cholecystokinin-B/gastrin receptor. Cloning and characterization. J. Biol. Chem. (1993) 268:8164–8169.
   PubMed Web of Science ®Google Scholar
• MALETINSKA L, LIGNON MF, GALAS MC: Pharma-cological characterization of new cholecystokinin analogues. Eur. J. Pharmacol. (1992) 222:233–240.
   PubMed Web of Science ®Google Scholar
• LOTTI VJ, PENDELTON RG, GOULD RJ, HANSON HM, CHANG RSD, CLINESCHMIDT BV: In vivo pharmacology of L-364,718, a new potent nonpeptide peripheral cholecystokinin antagonist. J. Pharmacol. Exp. Ther. (1987) 241:103-109. 59.
   Google Scholar
• SHINTAKU H, KATSUURA G, ISHIBASHI C, KATOH A, EIGYO M, MATSUSHITA A: A possible involvment of CCK-A receptor in ceruletide-induced protection against neuronal cell death following cerebral ischemia in mongolian gerbils. Jpn. J. Pharmacol. (1992) 58:253P.
   Google Scholar
• LYDIARD BR: Neuropeptides and anxiety: focus oncholecystokinin. Clin. Chem. (1994) 40:315–318.
   PubMed Web of Science ®Google Scholar
• BRADWEJIN J, KOSCZYCKI D, PAYEUR R, BOURIN M, BORTHWICK H: Replication of action of cholecys-tokinin tetrapeptide in panic disorder: clinical and behavioral findings. Am. J. Psychiatry (1992) 149:962–964.
   PubMed Web of Science ®Google Scholar
• HERNANDO F, FUENTES JA, ROQUES BO, RUIZ-GAYO M: The CCK-B receptor antagonist, L-365,260, elicits antidepressant-type effects in the forced-swim test in mice. Eur. J. Pharmacol. (1994) 261:257–623.
   PubMed Web of Science ®Google Scholar
• STANFA L, DICKENSON A, XU XJ, WIESENFELD-HALLIN Z: Cholecystokinin and morphine analgesia: variations on a theme. Trends Phamacol. ScL (1994) 15:65–66.
   PubMed Web of Science ®Google Scholar
• ITOH S, LAL H: Influences of cholecystokinin and analogs on memory processes. Drug Dev. Res. (1990) 21:257–276.
   Web of Science ®Google Scholar
• NAGATA A, ITO M, IWATA, KUNO J et al: G-protein coupled cholecystokinin-B/gastrin receptors are responsible for physiological cell growth of the stomach mucosa in vivo. Proc. Natl. Acad. ScL USA (1996) 93:11825–11830.
   PubMed Web of Science ®Google Scholar
• COEWIN RL, SMITH GP: Different effects of CCK antago-nists on gastrin-acid response to CCK and pentagas-trin. Peptides (1993) 14:253–257.
   PubMed Web of Science ®Google Scholar
• STEIERWALT RW, WILLIAMS JA: Binding specificity of the mouse cerebral cortex receptor for small cholecys-tokinin peptides. Regul PepL (1984) 8:51–59.
   PubMed Web of Science ®Google Scholar
• LIDDLE RA, ELASHOFF J, REEVE JR: Relative bioactivities of cholecystokinin-8 and -33 on rat pancreatic acini. Peptides (1986) 7:723–727.
   PubMed Web of Science ®Google Scholar
• NADZAN AM, KERWIN JF: Cholecystokinin agonists and antagonists. Ann. Rep. Med. Chem. (1991) 26:191–200.
   Web of Science ®Google Scholar
• ••Review about the CCK-R ligands.
   Google Scholar
• WETTSTEIN JG, BUÉNO L, JUNIEN JL: CCK antagonists: pharmacology and therapeutic interest. Pharmac. Ther. (1994) 62:267–284.
   PubMed Web of Science ®Google Scholar
• ••Interesting review on the therapeutic interest of CCK-Rantagonists. MAKOVEC F: CCK-B/gastrin receptor antagonists. Drugs Future (1993) 18:919-931. Highlight on the CCK-BR antagonists. TRIVEDI BK: Cholecystokinin receptor antagonists: Current Status. Curr. Med. Chem. (1994) 1:313-327. Description of the different CCK-R antagonists. FINK H, REX A, VOITS M, VOIGT JP: Major biological actions of CCK, a critical evaluation of research findings. Exp. Brain Res. (1998) 123:77-83. Critical evaluation of the testing model on CCK-R ligands activity.
   Google Scholar
• PENDLETON RG, BENDESKY RJ, SCHAFFER L, NOLAN TE, GOULD RJ, CLINESCHMIDT BV: Roles of endogenous cholecystokinin in biliary, pancreatic and gastric function: studies with L-364,718, a specific cholecys-tokinin receptor antagonist. J. Pharmacol. Exp. Ther. (1987) 241:110–116.
   PubMed Web of Science ®Google Scholar
• MODLIN IM, BILCHIK AJ, ZUCKER KA: Cholecystokinin of 'surgical' pancreatitis: benefit of receptor blockade. Arch. Surg. (1989) 124:574–578.
   PubMed Web of Science ®Google Scholar
• LI BASSI S, ROVALTI LC, GIACOVELLI G, BOLONDI L, BARBARA L: Effects of loxiglumide, a cholecystokinin antagonist, in non-ulcer dyspepsia. Gastroenterology (1990) 98:A77.
   Google Scholar
• MEIER R, THYMSHIRN M, MEYER B, ROVATI LC, GYR K, BEGLINGER C: Treatment of chronic constipation in geriatric patients with loxiglumide (Lox), a cholecys-tokinin antagonist. Gastroenterology (1990) 98:A374.
   Google Scholar
• CANN PA, ROVATI LC, SMART, SPILLER RC, WHORWELL PJ: Loxiglumide, a CCK-A antagonist, in irritable bowel syndrome: a pilot multicenter clinical study. Gastroen-terology (1993) 104:A486.
   Google Scholar
• JENSEN RT, JONES SW, GARDNER JD: COOH-terminal fragments of cholecystokinin. A new class of cholecys-tokinin receptor antagonists. Biochem. Biophys. Acta (1983) 757:250–258.
   PubMed Web of Science ®Google Scholar
• HAHNE WF, JENSEN RT, LEMP GF, GARDNER JD: Proglu-mide and benzotript: members of a different class of cholecystokinin receptor antagonists. Proc. Natl. Acad. ScL USA (1981) 78:6304–6308.
   PubMed Web of Science ®Google Scholar
• MAKOVEC F, BANI M, CHISTÉ R, REVEL L, ROVATI LC, SETNIKAR I: Different peripheral and central antago-nistic activity of new glutaramic acid derivatives on satiety induced by cholecystokinin in rats. Regul. Pept. (1986) 16:281–290.
   PubMed Web of Science ®Google Scholar
• SETNIKAR I, BANI M, CEREDA R et al.: Anticholecys-tokinin activities of loxiglumide. Arzneimittelforschung (1987) 37:1168–1171.
   PubMed Web of Science ®Google Scholar
• HIGGINBOTTOM M, HORWELL DC, ROBERTS E. Selective ligands for cholecystokinin receptor subtype CCK-A and CCK-B within a single structural class. Bioorg. Med. Chem. Lett. (1993) 3:881–884.
   Google Scholar
• GOETZ MA, LOPEZ M, MONAGHAN RL, CHANG RSL, LOTTI VJ, CHEN TB: Asperlicin, a novel non-peptidal cholecystokinin antagonist from aspergillus alliaceus, fermentation, isolation and biological properties. J. Antibiot. (1985) 38:1633–1637.
   PubMed Web of Science ®Google Scholar
• •First description of non-peptide CCK-R ligands.
   Google Scholar
• LOUIE DS, LIANG JP, OWYANG C : Charaterization of a new CCK antagonist, L-364-718: in vitro and in vivo studies. Am. J. Physiol. (1988) 255:261–266.
   Google Scholar
• ITO H, SOGABE H, NAKARAI T et al.: Pharmacological profile of FK480, a novel cholecystokinin type-A receptor antagonist: comparison to loxiglumide. J. Pharm. Exp. Ther. (1994) 268:571–575.
   PubMed Web of Science ®Google Scholar
• HOWBERT JJ, LOBB KL, BRITTON TC, MASON NR, BRUNS RF: Dip henylpyrazolidinone and benzodiazepine cholecystokinin antagonists: a case of convergent evolution in medicinal chemistry. Bioorg. Med. Chem. Lett. (1993) 3:875–880.
   Web of Science ®Google Scholar
• FLYNN DL, VILLAMIL CI, BECKER DP, GULLIKSON GW, MOUMMI C, YANG DC: 1,3,4-Trisubstituted pyrrolidi-nones as scaffolds for construction of peptidomimetic cholecystokinin antagonists. Bioorg. Med. Chem. Lett. (1992) 2:1251–1256.
   Web of Science ®Google Scholar
• MARTIN-MARTINEZ M, BARTOLOME-NEBREDA J, GOMEZ-MONTERREY I et al: Synthesis and stereo-chemical structure-activity relationship of 1,3-dioxoperhydropyrido[1,2- c] pyrimidine deriva-tives: potent and selective cholecystokinin-A receptor antagonists. J. Med. Chem. (1997) 40:3402–3407.
   PubMed Web of Science ®Google Scholar
• TACHIBANA I, KANAGAWA K, YAMAMOTO Y, OTSUKI M: Pharmacological profiles of a new serine derivative cholecystokinin receptor antagonist TP-680 on pancreatic biliary and gastric function. J. Pharmacol Exp. Ther. (1996) 279:1404–1412.
   PubMed Web of Science ®Google Scholar
• TANUGHI H, YAZAKI N, ENDO T, NAGASAKI M: Pharma-cological profile of T-0632, a novel potent and selective CCKA receptor antagonist, in vitro. Eur. J. Pharmacol. (1996) 304:147–154.
   PubMed Web of Science ®Google Scholar
• SIMMONS RD, BLOSSER JC, ROSAMOND JD: FDL 14294: a novel CCK-8 agonist with potent intranasal anorectic activity in the rat. Pharmacol. Biochem. Behav. (1994) 47:701–708.
   PubMed Web of Science ®Google Scholar
• PI-SUNYER F, KISSILEFF HR, THORNTON J, SMITH GP:C-Terminal octapeptide of cholecystokinin decreases food intake in obese men. Physiol. Behav. (1982) 29:627–630.
   PubMed Web of Science ®Google Scholar
• FROEHLICH F, GONVERS JJ, FRIED M: Role of nutrient fat and cholecystokinin in regulation of gallbladder emptying in man. Dig. Dis. ScL (1995) 40:529–533.
   PubMed Web of Science ®Google Scholar
• VAN DIJK A, RICHARDS JG, TRZECIAK A, GILLESSEN D, MOHLER H: Cholecystokinin receptors: biochemical demonstration and autoradiographical localization in rat brain and pancreas using [311] cholecystokinin-8 as radioligand. j Neurosci. (1984) 4:1221–1233.
   Google Scholar
• LIN CW, HOLLADAY MW, WITTE DG eta].: A71378: a CCK agonist with high potency and selectivity for CCK-A receptors. Am. J. Physiol. (1990) 258:G–648–651.
   Google Scholar
• SHIOSAKI K, LIN CW, KOPECKA H et al: Boc-CCK-4 derivatives containing side-chain ureas as potent and selective CCK-a receptor agonists. J. Med. Chem. (1991) 34:2837–2842.
   PubMed Web of Science ®Google Scholar
• PIERSON E, COMSTOCK JM, SIMMONS et al: Synthesisand biological evaluation of potent, hexapeptide CCK-A agonist anorectic agents. J. Med. Chem. (1997) 40:4302–4307.
   PubMed Web of Science ®Google Scholar
• HENKE BR, AQUINO CJ, BIRKEMO LS et al.: Optimizationof 3-(111-indazol-3-yl-methyl) -1,5-benzodiazepines as potent, orally active CCK-A agonists. J. Med. Chem. (1997) 40:2706–2725.
   PubMed Web of Science ®Google Scholar
• •Description of non-peptide CCK-AR agonists.
   Google Scholar
• HIRST GC, AQUINO C, BIRKEMO L et al Discovery of 1,5-benzodiazepines with peripheral cholecystokinin (CCK-A) receptor agonist activity (II): optimization of the C3 amino substituent. J. Med. Chem. (1996) 39:5236–5245.
   PubMed Web of Science ®Google Scholar
• SINGH L, FIELD MJ, HUGHES J et a/. :The behavioural properties of CI-988, a selective cholecystokininB receptor antagonist. Br. J. Pharmacol. (1 99 1) 104:239–245.
   Google Scholar
• RASMUSSEN K, STOCKTON ME, CZACHURA JF, HOWBERT JJ: Cholecystokinin (CCK) and schizo-phrenia: the selective CCKB antagonis LY262691 decreases midbrain dopamine unit activity. Eur. J. Pharmacol. (1991) 209:135–138.
   PubMed Web of Science ®Google Scholar
• CRESPI F: The role of cholecystokinin (CCK), CCK-A orCCK-B receptor antagonists in the spontaneous preference for drugs of abuse (alcohol or cocaine) in naive rats. Methods Find Exp. Clin. Pharmacol. (1998) 20:679–697.
   PubMed Web of Science ®Google Scholar
• •Action of CCK-R antagonists on drug and alcohol abuse.
   Google Scholar
• SEMPLE G, RYDER H, ROOKER DP et al.: (3R)-N-(1-(tert-butylcarbonylmethyl)-2,3-dihydro-2-oxo-5-(2-pyridy1)-1H-1,4-benzodiazepin-3-y1)-N- (3-(methylamino)phenyOurea (YF476): a potent and orally active gastrin/CCK-B antagonist. J. Med. Chem. (1997) 40:331–341.
   PubMed Web of Science ®Google Scholar
• MAKOVEC F, PERIS W, FRIGERIO S et al: Structure-activity relationships of new spiroglumide amido acid derivatives. J. Med. Chem. (1996) 39:135–142.
   PubMed Web of Science ®Google Scholar
• HUGHES J, BODEN P, COSTALL B et al: Development of a class of selective cholecystokinin type B receptor antagonists having potent amdolytic activity. Proc. Nati Acad. ScL USA (1990) 87:6728–6732.
   PubMed Web of Science ®Google Scholar
• TRIVEDI BK, PADIA JK, HOLMES A eta].: Second genera-tion `peptoid' CCK-B receptor antagonists: identifica-tion and development of N-(Adamantyl oxycarbony1)-a-methyl-(R)-tryptophan derivative (CI-1015) with an improved pharmacokinetic profile. J. Med. Chem. (1998) 41:38–45.
   Google Scholar
• BELLIER B, MCCORT-TRANCHEPAIN I, DUCOS B et al.: Synthesis and biological properties of new constrained CCK-B antagonists: discrimination of two states of the CCK-B receptor on transfected CHO cells. J. Med. Chem. (1997) 40:3947–3956.
   PubMed Web of Science ®Google Scholar
• PENDLEY CE, FITZPATRICK LR, CAPOLINO AJ et a/.:RP 73870, a gastrin/cholecystokinin-B receptor antago-nist with potent anti-ulcer activity in the rat. J. Pharmacol. Exp. Ther. (1995) 273:1015–1022.
   Google Scholar
• BOCK MG, DIPARDO RM, EVANS BE et al: Benzodi-azepine gastrin and brain cholecystokinin receptor ligands: L-365,260. J. Med. Chem. (1989) 32:13–16.
   PubMed Web of Science ®Google Scholar
• BOCK MG, DIPARDO RM, MELLIN EC et al.: Second-generation benzodiazepine CCK-B antagonists. Development of subnanomolar analogs with selectivity and water solubility. J. Med. Chem. (1994) 37: 722–724.
   Google Scholar
• CHAMBERS MS, HOBBS SC, GRAHAM MI etal.: Potent andselective water-soluble benzodiazepine-based CCKB receptor antagonists that contain lipophilic carboxy-late surrogates. Bioorg. Med. Chem. Lett. (1995) 5: 2303–2308.
   Google Scholar
• SATOH M, KONDOH Y, OKAMOTO Y et al.: New 1,4-benzodiazepin-2-onederivativesasfastrin/cholecystokinin-B antagonists. Chem. Pharm. Bull. (1995) 43:2159–2167.
   PubMed Web of Science ®Google Scholar
• SEMPLE G, RYDER H, ROOKER DP et al.: (3.11)-N- (1-(tert-butylcarbonylmethy0-2,3-dihydro-2-oxo-5-(2-pyridy1)-1H-1,4-benzodiazepin-3-y1)-N-(3-(methylamino)phenyOurea (TF476): a potent and orally active gastrin/CCK-B antagonist. J. Med. Chem. (1997) 40:331–341.
   Google Scholar
• FINIZIA G, DONATI D, OLIOSI B, TRANQUILLINI ME, URSINI A: Synthesis and evaluation of novel 1,5-benzodiazepines as potent and selective CCK-B ligands. Effect of substitution of the N-5 phenyl with alkyl groups. Bioorg. Med. Chem. Lett. (1996) 6:2957–2962.
   Web of Science ®Google Scholar
• DE TULLIO P, DELARGE J, PIROTTE B: Recent advances in the chemistry of cholecystokinin receptor ligands (agonists and antagonists). Curr. Merl. Chem. (1999) 6:433–455.
   PubMed Web of Science ®Google Scholar
• ABELSON JL, NESSE RM: Cholecystokinin-4 and panic. Arch. Gen. Psychiatry (1990) 47:395.
   PubMed Web of Science ®Google Scholar
• CRAWLEY JN: Cholecystokinin-dopamine interactions. Trends Pharmacol Scl (1991) 12:232–236.
   PubMed Web of Science ®Google Scholar
• ••Description of the complex relation between CCK anddopamine.
   Google Scholar
• LADURELLE N, KELLER G, BLOMMAERT A, ROQUES BP, DAUGE V: The CCK-B agonist, BC264, increases dopamine in the nucleus accumbens and facilitates motivation and attention after intraperitoneal injection in rats. Eur. j Neurochem. (1997) 9:1804–1814.
   Google Scholar
• HOLLADAY MW, BENNET MJ, TUFANO MD et al: Synthesis and biological activity of CCK heptapeptide analogues. Effects of conformational constraints and standard modifications on receptor subtype selectivity, functional activity in vitro and appetite suppression in vivo. J. Med. Chem. (1992) 35:2919–2928.
   Google Scholar
• DAUGE V, BOHME GA, CRAWLEY JN, DURIEUX C, STUTZMANN JM, FEGER J: Investigation of behavioral and electrophysiological responses induced by selective stimulation of CCKB receptors by using a new highly potent CCK analog, BC 264. Synapse (1990) 6:73–80.
   PubMed Web of Science ®Google Scholar
• HEIDBREDER C, ROQUES BP, DE WITTE P: Similar potencies of CCK-8 and its analogue BOC(N1e28;N1e31)CCK27-33 on the self-stimulation behaviour both are antagonized by a newly synthe-sized cyclic CCK analogue. Neuropeptides (1989) 13:89–94.
   PubMed Web of Science ®Google Scholar
• RODRIGUEZ M, LIGNON MF, GALAS MC, AMBLARD M, MARTINEZ J: Cyclic cholecystokinin analogues that are highly selective for rat and guinea pig central cholecystokinin receptors. Mol Pharmacol. (1990) 38: 333–341.
   PubMed Web of Science ®Google Scholar
• HOLLADAY MW, UN CW, MAY CS et al: Trans-3-n-propyl-L-proline is a highly favorable, conformation-ally restricted replacement for methionine in the C-terminal tetrapeptide of cholecystokinin. Stereose-lective synthesis of 3-allyl- and 3-n-propyl-t-proline derivatives from 4-hydroxy-t-proline. J. Merl. Chem. (1991) 34:455–457.
   Google Scholar
• BEINBORN M, QUINN SM, KOPIN AS: Minor modifica-tions of a cholecystokinin-B/gastrin receptor non peptide antagonist confer a broad spectrum of functional properties. J. Biol. Chem. (1998) 273:14146–14151.
   PubMed Web of Science ®Google Scholar
• •First description of a non-peptide CCK-B agonist.
   Google Scholar